

Development of anti-HLA-G/CD3 T-cell engaging bispecific antibody for the treatment of CRC patients



ONCOLOGY	Candidate
Product Type	Antibody-Like T cell Engager Product (Bispecific antibody)
Indication	1st indication: Colorectal Cancer (CRC) 2nd indication: HLA-G positive solid tumors
Target	Human Leukocyte Antigen G (HLA-G) and CD3
MoA(Mechanism of Action)	Direct killing of cancer cell by engaging T cell Blockade of HLA-G/ILT2 immune inhibitory pathway
Competitiveness	First in Class • ALiCE (Antibody-Like T cell Engager) format • A novel format with low toxicity, and high productivity
Development Stage	Candidate
Route of Administration	Parenteral-Intravenous